Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Contact:Dr. Lars WassillWerkstr. 2D-83555 Gars-BahnhofPhone: +49 (0) 8073 91693-0Fax: +49 (0) 8073 91693-33E-Mail: info@amplexdiagnostics.deInternet: www.amplexdiagnostics.deAmplexDiagnostics GmbH − Gesellschaftfür molekularbiologische DiagnostikBIOTECH DNA/PROTEIN ANALYTICSKeywords: Clinical Diagnostics, PCR, Infectious DiseasesAmplexDiagnostics GmbH is a privately held company for the development,production and distribution of In Vitro Diagnostics. Our aim is the improvementof the potential of the PCR-technology by implementing the mainadvantages of this technology into the diagnosis of bacterial infections.Founded in 2002 - Amplex developed its first product (hyplex © StaphyloResist)and entered the market already in 2003. Additional systems for the directdetection of multidrug-resistant bacteria (like VRE, ESBL, KPC and NDM-1)are completing our portfolio of PCR-screening tests for nosocomial infectionscausing bugs. Beside this we offer several PCR-based screening testsfor sexual transmitted diseases, EHEC or TBC. For further information pleasevisit our webpage www.hyplex.de or contact us.AMS Advanced Medical ServicesCROContact:Dr. Gerlinde JänelWerner-Eckert-Str. 10D-81829 MünchenPhone: +49 (0) 89 2000074-11Fax: +49 (0) 89 2000074-40E-Mail: gerlinde.jaenel@ams-europe.comInternet: www.ams-europe.comKeywords: Analysis, Pharmacology, Medical Writing, Monitoring, ClinicalResearchAMS Advanced Medical Services GmbH is a privately owned independentEuropean mid-size CRO founded in 1997 in Mannheim by 6 partners, 4 ofwhom are medical doctors. AMS has also offices in London, Vienna andMunich. AMS has an overall staff of 350 people, approx. half of them are inclinical research, the other half in Marketing and Sales services. AMSinvented the 1. Internet-Pharmaschool (1.IPS) with trainers and techniquesoffering tailor-made training concepts for staff in both clinical research andsales. AMS is a full service CRO with significant experience in multipletherapeutic areas and strong medical expertise covering Phase I to Phase IV,non-interventional programs, pharmaco-epidemiology and -economics.Our staff includes 60 CRAs and more than 50 people in DM and Stats.AMSilk GmbHBIOTECH AGRO, FOOD, ENVIRONMENTContact:Axel LeimerAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 38156-4430Fax: +49 (0) 89 38156-3859E-Mail: info@amsilk.comInternet: www.amsilk.comKeywords: Drug Delivery, Tissue Engineering / Cell Culture, Fine Chemicals /Reagents, New MaterialsTechnology enables the production of tailor-made materials which areunrivaled by most common synthetic materials. AMSilk addresses manyapplications and industry sectors with new materials enabling new productswith previously unachievable features.AMSilk has developed a unique process to produce biopolymers like spidersilk at an industrial scale. These materials form the basis for coatings, films,non-wovens and monofilament fibers. The resulting products are being developedmedical, pharmaceutical and industrial applications. The name AMSilkand the AMSilk Logo are registered trademarks of AMSilk GmbH; Munich.36